In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pemigatinib is an innovative targeted therapy that provides a new treatment opti···【more】
Release date:2024-08-13Recommended:457
Pemigatinibis mainly used to treat specific diseases such as advanced or metasta···【more】
Release date:2024-08-13Recommended:436
Pemigatinib is used in adults to treat bile duct cancer that has spread to other···【more】
Release date:2024-08-13Recommended:408
Pemigatinib is a targeted therapy drug developed by Incyte in the United States,···【more】
Release date:2024-08-12Recommended:385
Venetoclax is a drug used to treat leukemias, specifically chronic lymphocytic l···【more】
Release date:2024-08-09Recommended:470
Venetoclax is a BCL-2 inhibitor that selectively binds to BCL-2 protein and inhi···【more】
Release date:2024-08-09Recommended:424
Pemigatinib is a potent and selective oral antineoplastic drug targeting the FGF···【more】
Release date:2024-08-09Recommended:419
Pemigatinib is a targeted drug for cholangiocarcinoma, which has been marketed i···【more】
Release date:2024-08-09Recommended:328
Venetoclax is a drug used to treat chronic lymphocytic leukemia (CLL) and certai···【more】
Release date:2024-08-09Recommended:456
Capmatinib is a targeted drug manufactured by Novartis for the treatment of pati···【more】
Release date:2024-08-09Recommended:480
Capmatinib, trade name Tabrecta. It is an oral MET inhibitor mainly used for the···【more】
Release date:2024-08-09Recommended:463
Capmatinib is an oral, selective, ATP-competitive c-Met kinase inhibitor that in···【more】
Release date:2024-08-09Recommended:484